KKR Sells 5M BridgeBio Shares at $78 in Oversubscribed Secondary Offering
BBIO sits 72% above its 52-week low of $46.81 on light trading volume (0.4× avg).
Summary
KKR Genetic Disorder L.P. is selling 5 million BridgeBio shares at $78.00 each, a $390 million secondary offering that is oversubscribed and expected to close August 17. The company receives no proceeds, but the sale diversifies its institutional shareholder base. This follows KKR's earlier $1 billion preferred equity investment in July and a 13D/A showing Viking Global reducing its stake below 5% in July. The offering price is slightly below the current $80.40 market price, indicating modest discounting. Watch for completion on August 17 and any further stake reductions by existing holders.
At the time of this announcement, BBIO was trading at $80.40 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9B. The 52-week trading range was $46.81 to $93.42. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.